GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Employees - 17, CEO - Mr. David Alan Dodd, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -20.23, Piotroski Score(max is 10): 3, Working Capital: $7677073, Total Assets: $10833364, Retained Earnings: $-134713732, EBIT: -24525959, Total Liabilities: $2935334, Revenue: $5591439

AryaFin Target Price - $0.78 - Current Price $ - Analyst Target Price $